Dr Reddy's April-June quarter earnings have surpassed street estimates with net profit rising 14 percent to Rs 626 crore from Rs 550.4 crore in corresponding quarter last fiscal. Total income, - See more at: http://ways2capital-review.blogspot.in/2015/07/dr-reddys-q1-beats-street-net-rises-14.html#sthash.88GdPtaK.dpuf

Dr Reddy's April-June quarter earnings have surpassed street estimates with net profit rising 14 percent to Rs 626 crore from Rs 550.4 crore in corresponding quarter last fiscal. Total income, - See more at: http://ways2capital-review.blogspot.in/2015/07/dr-reddys-q1-beats-street-net-rises-14.html#sthash.88GdPtaK.dpuf

heart 1
Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829

Dr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829

The S&P BSE Sensex started on a cautious note on Wednesday following muted trend seen in other Asian markets. The fall in the index was led by losses in Dr Reddy's Laboratories, HDFC, Bharti Airtel, and ICICI Bank.  Get Expert Advice for Stock and Commodity Market Trading  www.marketmagnify.com/stock-cash-tips.php

The S&P BSE Sensex started on a cautious note on Wednesday following muted trend seen in other Asian markets. The fall in the index was led by losses in Dr Reddy's Laboratories, HDFC, Bharti Airtel, and ICICI Bank. Get Expert Advice for Stock and Commodity Market Trading www.marketmagnify.com/stock-cash-tips.php

The colour purple that has left drug makers like Dr Reddy's Laboratories pale | ET HealthWorld

The colour purple that has left drug makers like Dr Reddy's Laboratories pale | ET HealthWorld

Multiple Sclerosis Drug, Techfidera, from Biogen Has Been Approved by FDA

Multiple Sclerosis Drug, Techfidera, from Biogen Has Been Approved by FDA

pin 2
heart 1
Drugmaker Dr Reddy's Laboratories said it has signed a commercialisation deal with Australia's Hatchtech for the latter's prescription head lice product Xeglyze Lotion. - See more at: http://ways2capital-review.blogspot.in/2015/09/dr-reddys-signs-commercialisation-deal.html#sthash.HGFJaUwH.dpuf

Drugmaker Dr Reddy's Laboratories said it has signed a commercialisation deal with Australia's Hatchtech for the latter's prescription head lice product Xeglyze Lotion. - See more at: http://ways2capital-review.blogspot.in/2015/09/dr-reddys-signs-commercialisation-deal.html#sthash.HGFJaUwH.dpuf

heart 1
quit smoking

quit smoking

Arogya Finance Join Hands with Dr. Reddys Laboratories to Provide Medical Loans for the Financially Weak

Arogya Finance Join Hands with Dr. Reddys Laboratories to Provide Medical Loans for the Financially Weak

Dr Reddy's Laboratories, Japan's Eisai ink licensing pact for anticancer agent | ET HealthWorld

Dr Reddy's Laboratories, Japan's Eisai ink licensing pact for anticancer agent | ET HealthWorld

Shares of Dr Reddy’s Laboratories are currently trading 1.92% higher at Rs. 3,162 on BSE after the company announced the relaunch of Esomeprazole Magnesium capsules in US.

Shares of Dr Reddy’s Laboratories are currently trading 1.92% higher at Rs. 3,162 on BSE after the company announced the relaunch of Esomeprazole Magnesium capsules in US.

Pinterest • The world’s catalogue of ideas
Search